Allogene Therapeutics (ALLO)

• Market cap: $392M
• 1 day: 1.63%
• 5 days: -4.59%
• 1 month: -8.78%
• 3 months: -33.21%
• 6 months: -23.36%
• Year to date: -48.34%
• 1 year: -32.73%
• 5 years: -92.96%
• 10 years: -92.52%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Employees: 361

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

23% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 48

18% more capital invested

Capital invested by funds: $390M [Q2] → $460M (+$70.4M) [Q3]

1.56% less ownership

Funds ownership: 80.17% [Q2] → 78.61% (-1.56%) [Q3]

11% less funds holding

Funds holding: 171 [Q2] → 153 (-18) [Q3]

11% less call options, than puts

Call options by funds: $354K | Put options by funds: $399K

62% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 29

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 381% upside
• Avg. target: $9 381% upside
• High target: $9 381% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target	381% upside $9	Overweight Maintained	14 Nov 2024
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 36 / 155 met price target	381% upside $9	Buy Reiterated	8 Nov 2024